Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Polypharmacy and Cognitive and Physical Capability

Published: Tue, 26 Jun 2018 12:00:00 EDT
This study examined associations between polypharmacy in older adults and detailed measures of physical and cognitive capability. Is there a cumulative, dose-dependent relationship?
Journal of the American Geriatrics Society

Dementia and Risk of 30-Day Readmission in Older Adults

Published: Tue, 19 Jun 2018 12:00:00 EDT
Do older patients with dementia have a higher risk of hospital readmission within 30 days after discharge? How does primary diagnosis impact this risk?
Journal of the American Geriatrics Society

Telemedicine vs. In-person Follow-up After Neurosurgery

Published: Mon, 18 Jun 2018 12:00:00 EDT
Are telemedicine consultations a cost-saving alternative for follow-up care after elective neurosurgical procedures?
Neurosurgical Focus

Survival of Patients With Severe ARDS Treated Without ECMO

Published: Mon, 18 Jun 2018 12:00:00 EDT
A new study explores the survival rates of patients with severe ARDS who were managed without extracorporeal membrane oxygenation.
American Journal of Critical Care
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Chutes & Ladders—Alder poaches Juno executive for CEO

Published: Fri, 15 Jun 2018 13:58:23 +0000
Alder poaches Juno executive for CEO to prep for its migraine launch, Allergan brings in Abbott veteran after investors demand change, and ResTORbio hires Novartis researcher for clinical VP—these moves, plus more hirings, firings and retirings throughout the industry.

Bluebird preps E.U. filing for revamped thalassemia gene therapy

Published: Fri, 15 Jun 2018 13:10:46 +0000
With new data from a phase 1/2 trial of its LentiGlobin gene therapy in thalassemia in the bag, Bluebird Bio is pushing ahead with a European filing—and it could be that a follow-up in sickle cell disease is not too far behind.

GlaxoSmithKline's head of dermatology joins JAK developer Aclaris

Published: Fri, 15 Jun 2018 12:54:04 +0000
GlaxoSmithKline’s former head of dermatology R&D, David Gordon, has joined Aclaris Therapeutics as its new chief medical officer.

X4 targets year-end start for phase 3 WHIM trial after determining dose in midphase readout

Published: Fri, 15 Jun 2018 12:26:17 +0000
X4 Pharmaceuticals has established the X4P-001-RD dose to take forward into the pivotal stage of its phase 2/3 WHIM syndrome trial. Setting the dose of the CXCR4 inhibitor tees X4 up to start the phase 3 portion of the rare primary immunodeficiency disease trial before the end of the year.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy